STAT+: FDA announces a new priority review program in bid to further administration goals
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
WASHINGTON \u2014\u00a0The Food and Drug Administration is launching a program to reward companies with accelerated drug review and speedy agency feedback, if their actions align with the agency\u2019s national health priorities.\u00a0<\/p>\n
Those priorities include addressing unmet public health needs or health crises, beefing up domestic production of drugs, and delivering more innovative cures, according to a press release from the health department.\u00a0<\/p>\n
The Tuesday announcement lines up with the Trump administration\u2019s broader effort to achieve its health care priorities without issuing regulations. Among other steps, it is trying to push companies to lower drug prices<\/a> and build more factories in the U.S. by threatening dramatic tariffs and tying prices to those paid overseas.\u00a0<\/p>\n Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n